Search

Your search keyword '"Timmers, Gert-Jan"' showing total 21 results
Start Over Author "Timmers, Gert-Jan"
21 results on '"Timmers, Gert-Jan"'

1. Ixazomib, daratumumab and low-dose dexamethasone in intermediate-fit patients with newly diagnosed multiple myeloma: an open-label phase 2 trial

Author

Groen, Kaz, Stege, Claudia A.M., Nasserinejad, Kazem, de Heer, Koen, van Kampen, Roel J.W., Leys, Rineke B.L., Thielen, Noortje, Westerman, Matthijs, Wu, Ka-Lung, Ludwig, Inge, Issa, Djamila E., Velders, Gerjo A., Vekemans, Marie-Christiane, Timmers, Gert-Jan, de Boer, Fransien, Tick, Lidwine W., Verbrugge, Annelies, Buitenhuis, Danny, Cunha, Sonia M., van der Spek, Ellen, de Waal, Esther G.M., Sohne, Maaike, Sonneveld, Pieter, Nijhof, Inger S., Klein, Saskia K., van de Donk, Niels W.C.J., Levin, Mark-David, Ypma, Paula F., and Zweegman, Sonja

Published
2023
Full Text
View/download PDF

2. Improving the identification of frail elderly newly diagnosed multiple myeloma patients

Author

Stege, Claudia A. M., Nasserinejad, Kazem, Klein, Saskia K., Timmers, Gert-Jan, Hoogendoorn, Mels, Ypma, Paula F., Nijhof, Inger S., Velders, Gerjo A., Strobbe, Leonie, Durdu-Rayman, Nazik, Westerman, Matthijs, Davidis-van Schoonhoven, Marjan A., van Kampen, Roel J. W., Beeker, Aart, Koster, Ad, Dijk, Amanda C., van de Donk, Niels W. C. J., van der Spek, Ellen, Leys, Rineke B. L., Silbermann, Matthijs H., Groen, Kaz, van der Burg-de Graauw, Nicole C. H. P., Sinnige, Harm A. M., van der Hem, Klaas G., Levenga, Henriette, Bilgin, Yavuz M., Sonneveld, Pieter, Levin, Mark-David, and Zweegman, Sonja

Published
2021
Full Text
View/download PDF

3. Beyond static measurements: dynamic frailty improves survival prediction in multiple myeloma

Author

Smits, Febe, Groen, Kaz, Levin, Mark-David, Stege, Claudia A. M., van Kampen, Roel, van der Spek, Ellen, Bilgin, Yavuz M., Thielen, Noortje, Nijhof, Inger, Ludwig, Inge, de Waal, Esther G. M., Sandberg, Yorick, Kentos, Alain, Timmers, Gert-Jan, Regelink, Josien C., Westerman, Matthijs, de Heer, Koen, Vekemans, Marie-Christiane, Durdu-Rayman, Nazik, de Graauw, Nicole C. H. P., Seefat, Maarten R., van de Donk, Niels W. C. J., Ypma, Paula F., Nasserinejad, Kazem, and Zweegman, Sonja

Published
2025
Full Text
View/download PDF

4. Assessing frailty in myeloma:The pursuit of simplicity may sacrifice precision of predicting clinical outcomes

Author

Groen, Kazimierz, Smits, Febe, Nasserinejad, Kazem, Levin, Mark David, Regelink, Josien C., Timmers, Gert Jan, de Waal, Esther G.M., Westerman, Matthijs, Velders, Gerjo A., de Heer, Koen, Leys, Rineke B.L., van Kampen, Roel J.W., Stege, Claudia A.M., Seefat, Maarten R., Nijhof, Inger S., van der Spek, Ellen, Klein, Saskia K., van de Donk, Niels W.C.J., Ypma, Paula F., Zweegman, Sonja, Groen, Kazimierz, Smits, Febe, Nasserinejad, Kazem, Levin, Mark David, Regelink, Josien C., Timmers, Gert Jan, de Waal, Esther G.M., Westerman, Matthijs, Velders, Gerjo A., de Heer, Koen, Leys, Rineke B.L., van Kampen, Roel J.W., Stege, Claudia A.M., Seefat, Maarten R., Nijhof, Inger S., van der Spek, Ellen, Klein, Saskia K., van de Donk, Niels W.C.J., Ypma, Paula F., and Zweegman, Sonja

Published
2024

5. Assessing frailty in myeloma: The pursuit of simplicity may sacrifice precision of predicting clinical outcomes.

Author

Groen, Kazimierz, Smits, Febe, Nasserinejad, Kazem, Levin, Mark‐David, Regelink, Josien C., Timmers, Gert‐Jan, de Waal, Esther G. M., Westerman, Matthijs, Velders, Gerjo A., de Heer, Koen, Leys, Rineke B. L., van Kampen, Roel J. W., Stege, Claudia A. M., Seefat, Maarten R., Nijhof, Inger S., van der Spek, Ellen, Klein, Saskia K., van de Donk, Niels W. C. J., Ypma, Paula F., and Zweegman, Sonja

Published
2024
Full Text
View/download PDF

6. P877: IXAZOMIB DARATUMUMAB AND LOW-DOSE DEXAMETHASONE IN INTERMEDIATE-FIT PATIENTS WITH NEWLY DIAGNOSED MULTIPLE MYELOMA; RESULTS OF THE INDUCTION AND MAINTENANCE TREATMENT OF THE PHASE II HOVON 143 STUDY

Author

Groen, Kaz, primary, Stege, Claudia, additional, Nasserinejad, Kazem, additional, de Heer, Koen, additional, van Kampen, Roel J.W., additional, Leys, Rineke B.L., additional, Thielen, Noortje, additional, Westerman, Matthijs, additional, Wu, Ka-Lung, additional, Ludwig, Inge, additional, Issa, Djamila E., additional, Velders, Gerjo A., additional, Vekemans, Marie-Christiane, additional, van de Donk, Niels W.C.J., additional, Timmers, Gert-Jan, additional, de Boer, Fransien, additional, Tick, Lidwine W., additional, van der Spek, Ellen, additional, de Waal, Esther G.M., additional, Sohne, Maaike, additional, Sonneveld, Pieter, additional, Nijhof, Inger S., additional, Klein, Saskia K., additional, Levin, Mark-David, additional, Ypma, Paula F., additional, and Zweegman, Sonja, additional

Published
2023
Full Text
View/download PDF

7. Ixazomib, daratumumab and low-dose dexamethasone in intermediate-fit patients with newly diagnosed multiple myeloma:an open-label phase 2 trial

Author

Groen, Kaz, Stege, Claudia A.M., Nasserinejad, Kazem, de Heer, Koen, van Kampen, Roel J.W., Leys, Rineke B.L., Thielen, Noortje, Westerman, Matthijs, Wu, Ka Lung, Ludwig, Inge, Issa, Djamila E., Velders, Gerjo A., Vekemans, Marie Christiane, Timmers, Gert Jan, de Boer, Fransien, Tick, Lidwine W., Verbrugge, Annelies, Buitenhuis, Danny, Cunha, Sonia M., van der Spek, Ellen, de Waal, Esther G.M., Sohne, Maaike, Sonneveld, Pieter, Nijhof, Inger S., Klein, Saskia K., van de Donk, Niels W.C.J., Levin, Mark David, Ypma, Paula F., Zweegman, Sonja, Groen, Kaz, Stege, Claudia A.M., Nasserinejad, Kazem, de Heer, Koen, van Kampen, Roel J.W., Leys, Rineke B.L., Thielen, Noortje, Westerman, Matthijs, Wu, Ka Lung, Ludwig, Inge, Issa, Djamila E., Velders, Gerjo A., Vekemans, Marie Christiane, Timmers, Gert Jan, de Boer, Fransien, Tick, Lidwine W., Verbrugge, Annelies, Buitenhuis, Danny, Cunha, Sonia M., van der Spek, Ellen, de Waal, Esther G.M., Sohne, Maaike, Sonneveld, Pieter, Nijhof, Inger S., Klein, Saskia K., van de Donk, Niels W.C.J., Levin, Mark David, Ypma, Paula F., and Zweegman, Sonja

Abstract

Background: The outcome of non-transplant eligible newly diagnosed multiple myeloma (NDMM) patients is heterogeneous, partly depending on frailty level. The aim of this study was to prospectively investigate the efficacy and safety of Ixazomib-Daratumumab-low-dose dexamethasone (Ixa-Dara-dex) in NDMM intermediate-fit patients. Methods:In this phase II multicenter HOVON-143 study, IMWG Frailty index based intermediate-fit patients, were treated with 9 induction cycles of Ixa-Dara-dex, followed by maintenance with ID for a maximum of 2 years. The primary endpoint was overall response rate on induction treatment. Patients were included from October 2017 until May 2019. Trial Registration Number: NTR6297.Findings: Sixty-five patients were included. Induction therapy resulted in an overall response rate of 71%. Early mortality was 1.5%. At a median follow-up of 41.0 months, median progression-free survival (PFS) was 18.2 months and 3-year overall survival 83%. Discontinuation of therapy occurred in 77% of patients, 49% due to progression, 9% due to toxicity, 8% due to incompliance, 3% due to sudden death and 8% due to other reasons. Dose modifications of ixazomib were required frequently (37% and 53% of patients during induction and maintenance, respectively), mainly due to, often low grade, polyneuropathy. During maintenance 23% of patients received daratumumab alone. Global quality of life (QoL) improved significantly and was clinically relevant, which persisted during maintenance treatment. Interpretation: Ixazomib-Daratumumab-low-dose dexamethasone as first line treatment in intermediate-fit NDMM patients is safe and improves global QoL. However, efficacy was limited, partly explained by ixazomib-induced toxicity, hampering long term tolerability of this 3-drug regimen. This highlights the need for more efficacious and tolerable regimens improving the outcome in vulnerable intermediate-fi

Published
2023

8. Ixazomib, Daratumumab and Low Dose Dexamethasone in Intermediate-Fit Patients with Newly Diagnosed Multiple Myeloma (NDMM); Results of Induction Treatment of the Phase II HOVON 143 Study

Author

Groen, Kaz, primary, Stege, Claudia A.M., additional, Nasserinejad, Kazem, additional, de Heer, Koen, additional, Van Kampen, Roel J.W., additional, Leijs, Maria B.L., additional, Thielen, Noortje, additional, Westerman, Matthijs, additional, Wu, Ka Lung, additional, Ludwig, Inge, additional, Issa, Djamila, additional, Velders, Gerjo A., additional, Vekemans, Marie-Christiane, additional, van de Donk, Niels W.C.J., additional, Timmers, Gert-Jan, additional, Sonneveld, Pieter, additional, Seefat, Maarten R., additional, Croon-de Boer, Fransien, additional, Tick, Lidwine W., additional, van der Spek, Ellen, additional, De Waal, Esther G.M., additional, Sohne, Maaike, additional, Ypma, Paula F, additional, Nijhof, Inger S., additional, Klein, Saskia K., additional, Levin, Mark-David, additional, and Zweegman, Sonja, additional

Published
2021
Full Text
View/download PDF

9. Ixazomib, Daratumumab, and Low-Dose Dexamethasone in Frail Patients With Newly Diagnosed Multiple Myeloma: The Hovon 143 Study

Author

Stege, Claudia A. M., primary, Nasserinejad, Kazem, additional, van der Spek, Ellen, additional, Bilgin, Yavuz M., additional, Kentos, Alain, additional, Sohne, Maaike, additional, van Kampen, Roel J. W., additional, Ludwig, Inge, additional, Thielen, Noortje, additional, Durdu-Rayman, Nazik, additional, de Graauw, Nicole C. H. P., additional, van de Donk, Niels W. C. J., additional, de Waal, Esther G. M., additional, Vekemans, Marie-Christiane, additional, Timmers, Gert Jan, additional, van der Klift, Marjolein, additional, Soechit, Savita, additional, Geerts, Paul A. F., additional, Silbermann, Matthijs H., additional, Oosterveld, Margriet, additional, Nijhof, Inger S., additional, Sonneveld, Pieter, additional, Klein, Saskia K., additional, Levin, Mark-David, additional, and Zweegman, Sonja, additional

Published
2021
Full Text
View/download PDF

10. Dynamic Frailty Status Enables Better Prediction of Survival Probability - Results of the HOVON 143 Study

Author

Smits, Febe, Groen, Kaz, Levin, Mark-David, Stege, Claudia, Van Kampen, Roel JW, Van Der Spek, Ellen, Bilgin, Yavuz M, Thielen, Noortje, Nijhof, Inger S., Ludwig, Inge, De Waal, Esther G.M., Sandberg, Yorick, Kentos, Alain, Timmers, Gert Jan, Regelink, Josien C, Westerman, Matthijs, de Heer, Koen, Vekemans, Marie Christiane, Durdu-Rayman, Nazik, Graauw, Nicole de, Seefat, Maarten R., van de Donk, Niels WCJ, Ypma, Paula F, Nasserinejad, Kazem, and Zweegman, Sonja

Published
2023
Full Text
View/download PDF

11. Ixazomib, Daratumumab, and Low-Dose Dexamethasone in Frail Patients With Newly Diagnosed Multiple Myeloma: The Hovon 143 Study.

Author

UCL - (SLuc) Centre du cancer, UCL - SSS/IREC/SLUC - Pôle St.-Luc, UCL - (SLuc) Service d'hématologie, Stege, Claudia A M, Nasserinejad, Kazem, van der Spek, Ellen, Bilgin, Yavuz M, Kentos, Alain, Sohne, Maaike, van Kampen, Roel J W, Ludwig, Inge, Thielen, Noortje, Durdu-Rayman, Nazik, de Graauw, Nicole C H P, van de Donk, Niels W C J, de Waal, Esther G M, Vekemans, Marie-Christiane, Timmers, Gert Jan, van der Klift, Marjolein, Soechit, Savita, Geerts, Paul A F, Silbermann, Matthijs H, Oosterveld, Margriet, Nijhof, Inger S, Sonneveld, Pieter, Klein, Saskia K, Levin, Mark-David, Zweegman, Sonja, UCL - (SLuc) Centre du cancer, UCL - SSS/IREC/SLUC - Pôle St.-Luc, UCL - (SLuc) Service d'hématologie, Stege, Claudia A M, Nasserinejad, Kazem, van der Spek, Ellen, Bilgin, Yavuz M, Kentos, Alain, Sohne, Maaike, van Kampen, Roel J W, Ludwig, Inge, Thielen, Noortje, Durdu-Rayman, Nazik, de Graauw, Nicole C H P, van de Donk, Niels W C J, de Waal, Esther G M, Vekemans, Marie-Christiane, Timmers, Gert Jan, van der Klift, Marjolein, Soechit, Savita, Geerts, Paul A F, Silbermann, Matthijs H, Oosterveld, Margriet, Nijhof, Inger S, Sonneveld, Pieter, Klein, Saskia K, Levin, Mark-David, and Zweegman, Sonja

Abstract

Frail patients with newly diagnosed multiple myeloma have an inferior outcome, mainly because of a high discontinuation rate due to toxicity. We designed a phase II trial specifically for frail patients, evaluating the efficacy and tolerability of ixazomib-daratumumab-low-dose-dexamethasone (Ixa-Dara-dex). Sixty-five patients, who were frail according to the International Myeloma Working Group frailty index, were treated with nine induction cycles Ixa-Dara-dex followed by maintenance with Ixa-Dara for a maximum of 2 years. The overall response rate on induction therapy was 78%. After a median follow-up of 22.9 months, median progression-free survival (PFS) was 13.8 months and 12-month overall survival (OS) was 78%. Median PFS and 12-month OS were 21.6 months and 92% in patients who were frail based on age > 80 years alone, versus 13.8 months and 78%, and 10.1 months and 70% in patients who were frail based on additional frailty parameters either ≤ 80 or > 80 years of age, respectively. In 51% of patients, induction therapy had to be discontinued prematurely, of which 6% because of noncompliance to study treatment, 9% because of toxicity, and 9% because of death (8% within 2 months, of which 80% because of toxicity). Quality of life improved during induction treatment, being clinically meaningful already after three induction cycles. Ixa-Dara-dex lead to a high response rate and improved quality of life. However, treatment discontinuation because of toxicity and early mortality, negatively influencing PFS and OS, remains a concern in frail patients. The outcome was heterogeneous across frail subpopulations. This should be taken into account in the design and interpretation of future studies in frail patients, to pave the way for more precise treatment guidance.

Published
2021

12. Improving the identification of frail elderly newly diagnosed multiple myeloma patients

Author

Stege, Claudia A.M., Nasserinejad, Kazem, Klein, Saskia K., Timmers, Gert Jan, Hoogendoorn, Mels, Ypma, Paula F., Nijhof, Inger S., Velders, Gerjo A., Strobbe, Leonie, Durdu-Rayman, Nazik, Westerman, Matthijs, Davidis-van Schoonhoven, Marjan A., van Kampen, Roel J.W., Beeker, Aart, Koster, Ad, Dijk, Amanda C., van de Donk, Niels W.C.J., van der Spek, Ellen, Leys, Rineke B.L., Silbermann, Matthijs H., Groen, Kaz, van der Burg-de Graauw, Nicole C.H.P., Sinnige, Harm A.M., van der Hem, Klaas G., Levenga, Henriette, Bilgin, Yavuz M., Sonneveld, Pieter, Levin, Mark David, Zweegman, Sonja, Stege, Claudia A.M., Nasserinejad, Kazem, Klein, Saskia K., Timmers, Gert Jan, Hoogendoorn, Mels, Ypma, Paula F., Nijhof, Inger S., Velders, Gerjo A., Strobbe, Leonie, Durdu-Rayman, Nazik, Westerman, Matthijs, Davidis-van Schoonhoven, Marjan A., van Kampen, Roel J.W., Beeker, Aart, Koster, Ad, Dijk, Amanda C., van de Donk, Niels W.C.J., van der Spek, Ellen, Leys, Rineke B.L., Silbermann, Matthijs H., Groen, Kaz, van der Burg-de Graauw, Nicole C.H.P., Sinnige, Harm A.M., van der Hem, Klaas G., Levenga, Henriette, Bilgin, Yavuz M., Sonneveld, Pieter, Levin, Mark David, and Zweegman, Sonja

Published
2021

13. P-116 The simplified frailty index (S-FI) identifies a less vulnerable population of frail patients than patients who are defined frail using the International Myeloma working Group Frailty index (IMWG-FI)

Author

Groen, Kaz, Smits, Febe, Nasserinejad, Kazem, Levin, Mark-David, Regelink, Josien, Timmers, Gert-Jan, de Waal, Esther, Westerman, Matthijs, Velders, Gerjo, de Heer, Koen, Leys, Rineke, van Kampen, Roel, Stege, Claudia, Seefat, Maarten, Nijhof, Inger, van der Spek, Ellen, Klein, Saskia, van de Donk, Niels, Ypma, Paula, and Zweegman, Sonja

Published
2023
Full Text
View/download PDF

16. Efficacy and Tolerability of Ixazomib, Daratumumab and Low Dose Dexamethasone (Ixa Dara dex) in Unfit and Frail Newly Diagnosed Multiple Myeloma (NDMM) Patients; Results of the Interim Efficacy Analysis of the Phase II HOVON 143 Study

Author

Stege, Claudia A.M., primary, Nasserinejad, Kazem, primary, van der Spek, Ellen, primary, Van Kampen, Roel J.W., primary, Sohne, Maaike, primary, Thielen, Noortje, primary, Bilgin, Yavuz, primary, De Waal, Esther G.M., primary, Ludwig, Inge, primary, Leijs, Maria B.L., primary, Kentos, Alain, primary, Timmers, Gert Jan, primary, de Heer, Koen, primary, Westerman, Matthijs, primary, Vekemans, Marie Christiane, primary, Durdu-Rayman, Nazik, primary, van der Burg-de Graauw, Nicole C.H.P., primary, Van De Donk, Niels W. C. J., primary, Sonneveld, Pieter, primary, Klein, Saskia K., primary, Levin, Mark-David, primary, and Zweegman, Sonja, primary

Published
2019
Full Text
View/download PDF

17. Efficacy of Internet-Based Cognitive Behavioral Therapy for Treatment-Induced Menopausal Symptoms in Breast Cancer Survivors: Results of a Randomized Controlled Trial

Author

Atema, Vera, primary, van Leeuwen, Marieke, additional, Kieffer, Jacobien M., additional, Oldenburg, Hester S.A., additional, van Beurden, Marc, additional, Gerritsma, Miranda A., additional, Kuenen, Marianne A., additional, Plaisier, Peter W., additional, Lopes Cardozo, Alexander M.F., additional, van Riet, Yvonne E.A., additional, Heuff, Gijsbert, additional, Rijna, Herman, additional, van der Meij, Suzan, additional, Noorda, Eva M., additional, Timmers, Gert-Jan, additional, Vrouenraets, Bart C., additional, Bollen, Matthé, additional, van der Veen, Henk, additional, Bijker, Nina, additional, Hunter, Myra S., additional, and Aaronson, Neil K., additional

Published
2019
Full Text
View/download PDF

18. Beyond static measurements: dynamic frailty improves survival prediction in multiple myeloma

Author

Smits, Febe, Groen, Kaz, Levin, Mark-David, Stege, Claudia A. M., van Kampen, Roel, van der Spek, Ellen, Bilgin, Yavuz M., Thielen, Noortje, Nijhof, Inger, Ludwig, Inge, de Waal, Esther G. M., Sandberg, Yorick, Kentos, Alain, Timmers, Gert-Jan, Regelink, Josien C., Westerman, Matthijs, de Heer, Koen, Vekemans, Marie-Christiane, Durdu-Rayman, Nazik, de Graauw, Nicole C. H. P., Seefat, Maarten R., van de Donk, Niels W. C. J., Ypma, Paula F., Nasserinejad, Kazem, and Zweegman, Sonja

Abstract

The level of frailty, according to the International Myeloma Working Group frailty index, is highly dynamic during antimyeloma treatment. Dynamic frailty assessment improved the prediction of survival and early mortality compared with the prognostic value of static frailty level at baseline.

Published
2024
Full Text
View/download PDF

19. R-DHAP Immunochemotherapy Is An Effective Remission-Induction Treatment For CLL Patients With Fludarabine Refractory Disease With Or Without Deletion 17p, Enabling The Majority To Proceed To Allogeneic Stem Cell Transplantation

Author

Van Gelder, Michel, primary, Ghidey, Wendim, additional, Chamuleau, Martine ED, additional, Cornelissen, Jan, additional, Petersen, Eefke J, additional, Daenen, Simon M. G. J., additional, Zachee, Pierre, additional, Hoogendoorn, Mels, additional, Beker, Aart, additional, Timmers, Gert Jan, additional, Kater, Arnon P., additional, and Van Oers, Marinus H.J., additional

Published
2013
Full Text
View/download PDF

20. Efficacy of Cognitive Behavioral Therapy and Physical Exercise in Alleviating Treatment-Induced Menopausal Symptoms in Patients With Breast Cancer: Results of a Randomized, Controlled, Multicenter Trial.

Author

Duijts, Saskia F. A., van Beurden, Marc, Oldenburg, Hester S. A., Hunter, Myra S., Kieffer, Jacobien M., Stuiver, Martijn M., Gerritsma, Miranda A., Menke-Pluymers, Marian B. E., Plaisier, Peter W., Rijna, Herman, Lopes Cardozo, Alexander M. F., Timmers, Gert Jan, van der Meij, Suzan, van der Veen, Henk, Bijker, Nina, de Widt-Levert, Louise M., Geenen, Maud M., Heuff, Gijsbert, van Dulken, Eric J., and Boven, Epie

Published
2012
Full Text
View/download PDF

21. Cefpirome as empirical treatment for febrile neutropenia in patients with hematologic malignancies.

Author

Timmers GJ, van Vuurden DG, Swart EL, Simoons-Smit AM, and Huijgens PC

Subjects
Aged, Anti-Bacterial Agents toxicity, Cephalosporins toxicity, Female, Hematologic Neoplasms pathology, Humans, Male, Middle Aged, Cefpirome, Anti-Bacterial Agents therapeutic use, Cephalosporins therapeutic use, Fever drug therapy, Hematologic Neoplasms drug therapy, Neutropenia drug therapy
Abstract

Cefpirome, a fourth generation cephalosporin, was administered during 154 episodes of febrile neutropenia in 106 patients. We assessed the clinical efficacy of cefpirome and its activity against isolated pathogens in neutropenic patients with hematologic malignancies. In addition, the pharmacokinetics and optimal dosing regimen of cefpirome during neutropenia were investigated.

Published
2005

Catalog

Books, media, physical & digital resources
See catalog results